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Abstract
Introduction: Previous studies, mostly from Africa, have shown that serum cryptococcal antigenemia may precede the
development of cryptococcal meningitis and early death among patients with advanced HIV infection.We examined cryptococcal
antigenemia as a risk factor for HIV-associated mortality in Indonesia, which is experiencing a rapidly growing HIV epidemic.
Methods: We included ART-naı¨ve HIV patients with a CD4 cell count below 100 cells/mL and no signs of meningitis in an
outpatient HIV clinic in Bandung, West Java, Indonesia. Baseline clinical data and follow-up were retrieved from a prospective
database, and cryptococcal antigen was measured in stored serum samples using a semiquantitative lateral flow assay. Cox
regression analysis was used to identify factors related to mortality.
Results: Among 810 patients (median CD4 cell count 22), 58 (7.1%) had a positive cryptococcal antigen test with a median titre
of 1:80 (range: 1:1 to 1:2560). Cryptococcal antigenemia at baseline was strongly associated with the development of
cryptococcal meningitis and early death and loss to follow-up. After one year, both death (22.4% vs. 11.6%; p0.016; adjusted
HR 2.19; 95% CI 1.784.06) and the combined endpoint of death or loss to follow-up (67.2% vs. 40.4%; pB0.001; adjusted HR
1.57; 95% CI 1.122.20) were significantly higher among patients with a positive cryptococcal antigen test.
Conclusions: Cryptococcal antigenemia is common and clinically relevant among patients with advanced HIV in this setting.
Routine screening for cryptococcal antigen followed by lumbar puncture and pre-emptive antifungal treatment for those who
are positive may help in reducing early mortality.
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Introduction
Cryptococcal meningitis is a major cause of subacute meningi-
tis and death in patients with advanced HIV infection, affecting
an estimated one million people each year, especially in sub-
Saharan Africa [1,2]. Cryptococcal meningitis is usually diag-
nosed by microscopic detection or culture of cryptococcus
from cerebrospinal fluid (CSF), or detection of cryptococcal
antigen in CSF or serum [35]. Serum cryptococcal antigen has
also been found in HIV patients without clinical meningitis. In a
cohort in South Africa, cryptococcal antigen screening ade-
quately identified patients at risk for cryptococcal meningitis
and death [6].Therefore, pre-emptive antifungal treatment for
patients with asymptomatic serum cryptococcal antigenemia
has been advocated [7,8]. Besides the South African study, sev-
eral studies, most of them smaller, have been published from
Uganda,Thailand and Cambodia [3,913].We report the largest
cohort study so far, from Indonesia, which has one of the most
rapidly growing HIV epidemics in Asia [14]. Most HIV patients
in Indonesia present with advanced disease, and early mor-
tality is very high [15].We determined the prevalence of serum
cryptococcal antigenemia and its effect on mortality among
ART-naı¨ve patients with a CD4 count below 100 cells/mL.
Methods
Setting and design
The study was conducted in Hasan Sadikin Hospital, the top
referral hospital which serves the 42 million people of West
Java Province, Indonesia. Since December 2004, integrated
in- and outpatient services are provided for HIV-positive
individuals. Services include HIV counselling and testing, HIV
treatment and management of opportunistic infections. Since
September 2007, patients are included into a cohort study
and characterized prospectively using a standard question-
naire, physical examination and laboratory examination.
Baseline blood samples are archived for all patients. Patients
on ART generally visit the clinic monthly, with scheduled
clinical and laboratory follow-up, including the measurement
of CD4 cell count and plasma HIV-RNA [16]. Patients with
symptoms suggesting central nervous system infection are
referred to a neurologist for further investigations. CSF, if
taken, is examined for M. tuberculosis, bacteria and crypto-
coccus [17]. Cryptococcal meningitis is diagnosed if crypto-
coccus is found in CSF, either with direct India ink staining or
culture, or if cryptococcal antigen testing is positive. Patients
diagnosed with cryptococcal meningitis are treated with
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either oral fluconazole or intravenous amphotericin B [17].
In-hospital death is recorded in medical records; outpatients
are classified as dead if reported by family or community
organizations or confirmed by telephone calls from the clinic.
Patients not returning to the clinic are traced by telephone
calls. No home visits are done as confidentiality might be
breached since many patients do not disclose their HIV status
to others. Baseline data and follow-up are recorded in an
electronic database.
For this particular study, we included newly diagnosed HIV-
positive adult patients presenting to the outpatient clinic
between November 2007 and October 2011. Only ART-naı¨ve
patients with a CD4 count below 100 cells/mL were eligible
for the study. Subjects with a diagnosis of cryptococcal
meningitis on admission were excluded. Patient data needed
for this study including sex, age, CD4 cell count, plasma HIV-
RNA concentration (‘‘viral load’’), body mass index (BMI),
baseline history of illness and follow-up were retrieved from
a database of the HIV clinic. Tuberculosis (TB) at time of
enrolment was defined as TB treatment started at some
point between one month before and one month after
baseline. The definition of cerebral toxoplasmosis was based
on a physician’s decision to start treatment with pyrimetha-
mine and clindamycin for presumed cerebral toxoplasmosis.
Oral candidiasis was diagnosed clinically. During follow-up,
the time until initiation of ART was recorded, and clinical
response was defined as alive, dead, lost to follow-up, or
transferred out. Length of follow-up was counted from the
day of inclusion until the date of death or the most recent
date the patient was known to be alive. Patients were
considered lost to follow-up if they had not returned to the
HIV clinic within six months if ART-naive, or three months if
already taking ART, and the last date they visited the clinic
plus one day was considered the date of loss to follow-up.
Ethics statement
Anonymous blood samples were retrieved from an already-
existing hospital collection, collected as part of baseline
laboratory assessment for patients included in the HIV cohort
and approved by the Ethical Committee of Hasan Sadikin
Hospital/Medical Faculty of Universitas Padjadjaran, Bandung,
Indonesia (No. 114/FKUP-RSHS/KEPK/Kep./EC/2007). Infor-
med consent had been asked prior to participation into the
cohort, including consent to use archived samples; therefore,
no separate consent was asked for this particular study.
Laboratory examinations
Cryptococcal antigen testing was done using a lateral flow
assay (LFA, Immuno-Mycologics, Norman, Oklahoma, USA), a
recently developed and reliable point-of-care test approved by
the US Food and Drug Administration [8]. For this study, serum
cryptococcal antigen was measured retrospectively using
serum samples archived at the time of enrolment in HIV-care
(‘‘baseline’’). Quantification of the concentration of crypto-
coccal antigen in all positive samples was done using LFA
according to the manufacturer’s instruction. LFA titres were
determined semiquantitatively by diluting samples in LFA
diluent solution and assessing reactivity as described above.
The highest sample dilution that produced a positive result as
read by three observers was recorded as the LFA titre.
Data analysis and statistics
Baseline characteristics of patients with and without crypto-
coccal antigenemia were compared. Continuous variables are
presented as mean (standard deviation) if normally distrib-
uted and median (interquartile range, IQR) if not normally
distributed, and categorical variables as percentage. Differ-
ences between groups were compared using Chi-square test
for proportions and Mann-Whitney U test for continuous
variables, with pB0.05 considered statistically significant.
Progression to the primary endpoints death and a composite
endpoint of death or loss to follow-up was examined by
KaplanMeier estimates. Associations between cryptococcal
antigenemia and these endpoints were examined using Cox
regression. In multivariable Cox regression, we adjusted for
possible confounding factors including CD4 cell count,
haemoglobin, ART (as a time-dependent variable), oral
candidiasis, toxoplasmosis and TB treatment, age and gender.
Multiple imputation (five times imputation) was performed
for time of death (as outcome), WHO clinical stage, and body
height and weight, with assumption that all predictors were
missing at random. All variables including time of death were
used as predictors. Variables with pB0.100 in univariable
analysis were included in the multivariable Cox regression
model, and the final model was determined by backward
selection. Statistical analysis was done by SPSS version 18.0.2
(IBM). The analysis presented used pooled data from the
imputation, unless stated otherwise. Survival curves were
drawn using GraphPad Prism version 5.0.
Results
From 1948 patients registered in the HIV clinic during study
period, 857 patients were eligible and 810 could be included
in the study (Figure 1). Patients were mostly young males
presenting with advanced disease and a very low CD4 cell
count. Headache was reported by one of 266 patients for
whom this information was available. Fifty-eight patients
(7.1%) had a positive cryptococcal antigen test. There were
no significant statistical differences in socio-demographic
characteristics, clinical status, laboratory parameters, and
symptoms at presentation between patients with and with-
out serum cryptococcal antigen, except for WHO clinical
staging as recorded in the medical records (Table 1).
Fluconazole was used at time of inclusion by 120 out of
324 patients (37.0%) for whom this information was avail-
able. Fluconazole use was more common in patients who
were found to have a positive cryptococcal antigen test (18/
30; 60%), than in patients who tested negative (102/294;
35%). Titration of serum cryptococcal antigen using LFA
showed a median titre of 1:80 (range: 1:11:2560). We found
a weak correlation between CD4 cell count and the titre of
cryptococcal antigen (r0.309, p0.056).
Patients were followed for a median 343 (IQR 211000)
days (total observation: 1190 patient years). A total of 561
patients (69.3%) started ART, after a median of 24 (IQR 14
42) days. After one year, 100 patients had died and 243
patients were lost to follow-up, corresponding with 12.3%
one-year mortality and 30.0% one-year loss to follow-up.
Death and loss to follow-up especially occurred during the
first few months; 39 patients (39.0% of all deaths in one year)
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died within one month, and another 155 patients (63.8% of
all patients lost to follow-up in one year) did not return after
their initial visit.
During follow-up, six out of 58 patients (10.3%) with a
positive cryptococcal antigen test were diagnosed with
cryptococcal meningitis, while none of the 752 patients
with a negative test did so. The cases of cryptococcal
meningitis were diagnosed after a median of 91 days (range
17219 days); three patients were diagnosed within three
weeks after starting ART. Two out of six patients with
confirmed cryptococcal meningitis died despite treatment
with amphotericin B. The risk of developing cryptococcal
HIV-infected patients*
(n=1948)
Eligible patients
(n=857)
No serum samples available
(n=47)
Included into the study
(n=810)
Excluded
• CD4 cell count not available (n=195)
• CD4 count >100 cells/µL (n=841)
• ART before baseline (n=44)
• Cryptococcal meningitis (n=11)
Figure 1. Patient flow.
*All HIV-positive patients included in the HIV clinic cohort during the study period (20072011) .
Table 1. Baseline characteristics of patients according to cryptococcal antigenemia statusa
All patients (n810) CrAg-positive (n58) CrAg-negative (n752) p
Socio-demographics
Age, year (IQR) 30 (2734) 30 (2532) 30 (2734) 0.345
Male sex (%) 76.3 72.4 76.6 0.471
History of injecting drug use (%) 59.7 62.2 59.5 0.721
Clinical status
WHO clinical stage 4 (%) 66.0 81.1 64.8 0.016
BMIB18.5 kg/m2 (%) 59.2 70.4 58.6 0.225
Laboratory parameters
CD4 cells/mL, median (IQR) 20 (745) 18 (437) 21 (745) 0.327
HIV-RNA/mL, log (IQR) 5.2 (4.45.6) 5.0 (4.85.7) 5.2 (4.35.6) 0.923
Haemoglobin in g/dL, median (IQR) 11.3 (9.612.9) 11.1 (9.512.5) 11.4 (9.612.9) 0.322
Anaemiab (%) 68.9 75.9 68.4 0.248
Positive HBsAg (%) 7.7 2.2 8.1 0.144
Positive anti-HCV (%) 60.7 59.6 60.7 0.875
Symptoms at presentation
Fever (%) 43.9 44.8 43.8 0.884
Cough1 week (%) 34.6 36.2 34.5 0.789
Weight loss10% (%) 58.9 58.6 58.9 0.969
Co-infections at presentation
TB treatment (%) 19.2 17.2 19.3 0.700
Cerebral toxoplasmosis treatment (%) 9.3 12.1 9.0 0.444
Oral candidiasis (%) 56.7 66.7 56.0 0.138
aData were missing for TB treatment (n1), haemoglobin (n19), weight loss (n20), cough (n21), fever (n22), oral candidiasis (n82),
history of IDU (n88), WHO clinical stage (n115), HBsAg (n187), anti-HCV (n195), BMI (n271), HIV-RNA (n720). bAnaemia was
defined as511.0 g/dL for females and513.0 g/dL for males. CrAgcryptococcal antigen test.
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meningitis was not associated with the cryptococcal antigen
titre (median titre 1:80 (IQR 1:51:1216) for those who
developed meningitis vs. 1:40 (IQR 1:61: 4480) for those
who did not; p0.813).
The date of death was missing for seven patients, for
whom multiple imputations were performed. All variables
had a similar distribution among those with missing data.
A positive cryptococcal antigen test was clearly associated
with increased mortality in one year, i.e. 22.4% vs. 11.6%, as
also shown in the survival analysis in Figure 2A (HR 2.57, 95%
CI 1.434.60; p0.002). Mortality remained significantly
higher among patients with a positive cryptococcal antigen
test after two (22.4% vs. 11.7%) and three years (24.1% vs.
12.9%). Loss to follow-up was also higher among patients
with a positive cryptococcal antigen test as compared to
those with negative result (44.8% vs. 28.9%, p0.011). It is
likely that some patients who were lost to follow-up may
actually have died, especially those who dropped out during
the first few months. Indeed, more patients with a positive
cryptococcal antigen test did not return after their initial visit
to the clinic (29.3% vs. 22.5%), and more had reached the
combined endpoint of death or loss to follow-up after one
year (HR 2.05, 95% CI 1.472.86; pB0.001; Figure 2B).
Besides cryptococcal antigenemia, other factors associated
with one-year mortality included ART administration, low CD4
cell count, anaemia at baseline, WHO clinical stage 4,
Figure 2. (A) Death in one year and (B) combined death or loss to follow-up in one year of subjects with and without cryptococcal
antigenemia.
CrAgpositive cryptococcal antigen test; CrAgnegative cryptococcal antigen test.
Date of death was missing for seven patients (one CrAg and six CrAg), who are not included in the survival curve in Figure 2A.
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BMIB18.5 kg/m2, a high plasma HIV-RNA and oral candidiasis.
After correction for other factors, cryptococcal antigenemia
remained significantly associated with one-year survival
(Table 2) and the combined endpoint of death or loss to
follow-up (Table 3).
ART was associated with a survival benefit. It reduced the
risk of dying by 61% with every month of ART administration
(pB0.001). CD4 cells count reduced the risk by 8.5% with
every 10 cells increment (pB0.001). This benefit of having
ART was significant for both cryptococcal antigen-positive
and -negative cases, although the benefit was more promi-
nent in the group of patients with cryptococcal antigenemia
(risk reduction of 73.3% vs. 58.7%). Higher CD4 cells were
only beneficial in those without cryptococcal antigen (risk
reduction 9.1% with every 10 cells increment, pB0.001).
Discussion
In this cohort of 810 patients with advanced HIV infection
but with no clinical suspicion of meningitis, 7.1% had a posi-
tive serum cryptococcal antigen test. Those with a positive
result had a much higher chance of developing cryptococcal
meningitis (10.3% vs. 0%), and a higher chance of early loss
Table 2. Factors associated with one-year mortalitya
Univariableb Final modelc
Dead (n100) Alive (n467) HR (95% CI) p HR (95% CI) p
ART (time dependent)   0.39 (0.250.60) B0.001 0.44 (0.270.71) 0.001
Positive cryptococcal Ag (%) 13.0 4.1 2.57 (1.434.60) 0.002 2.19 (1.784.06) 0.013
Male sex (%) 72.0 78.4 0.74 (0.481.15) 0.181  
Age in years, median 31 30 1.02 (0.991.05) 0.261  
CD4 cells/mL, median 11 23 0.98 (0.981.00) 0.004  
WHO stage 4 (%) 82.0 58.4 2.81 (1.375.79) 0.007 2.28 (1.174.43) 0.017
HIV-RNA in log/mL, median 5.45 5.16 2.34 (1.214.53) 0.011  
Anaemiad (%) 83.0 63.5 2.59 (1.534.37) B0.001  
Oral candidiasis (%) 66.0 52.0 2.50 (1.544.05) B0.001 2.26 (1.383.65) 0.001
Cerebral toxoplasmosis (%) 13.0 8.7 1.25 (0.931.69) 0.445  
TB at admission (%) 17.0 19.4 0.76 (0.850.99) 0.300  
aThis table excludes those who were lost to follow-up. Cox regression was performed using pooled data from multiple imputations. Data were
missing for anaemia (n8), candidiasis (n56),WHO clinical stage (n115). BMI (n115), HIV-RNA (n473). bVariables with p0.100 were
not included in multivariable analysis. cHIV-RNA and BMI were not included in the final model because of the many missing values. Candidiasis
was not included in the final model because of the possible interaction with WHO stage. dAnaemia was defined asB11.0 g/dL for female
andB13.0 g/dL for male.
Table 3. Cox regression analysis of composite end point death and loss to follow-up in one yeara
Univariableb Final modelc
Dead or lost to FU n343 Alive n467 HR (95% CI) p HR (95% CI) p
ART (time dependent)   0.24 (0.190.31) B0.001 0.24 (0.190.32) B0.0001
Positive cryptococcal Ag (%) 11.4 4.1 2.05 (1.472.86) B0.001 1.57 (1.122.20) 0.009
Age in year, median 30 30 1.01 (1.001.03) 0.084  
Male sex (%) 78.2 78.4 0.81 (0.641.03) 0.090 0.75 (0.590.96) 0.022
CD4 cell count, median 15 23 0.99 (0.991.00) B0.001 0.99 (0.991.00) 0.002
WHO stage 4 (%) 74.9 58.4 1.79 (1.272.51) 0.002 1.62 (1.162.28) 0.007
HIV-RNA in log/mL, median 5.39 5.08 1.78 (1.182.70) 0.006  
Anaemiad (%) 76.4 63.5 1.65 (1.282.13) B0.001 1.46 (1.131.91) 0.004
BMI in kg/m2, median 17.19 18.08 1.49 (1.102.02) 0.011  
Oral candidiasis (%) 63.3 52.0 1.41 (1.111.78) 0.004  
Cerebral toxoplasmosis (%) 8.2 10.1 0.77 (0.640.94) 0.195  
TB at admission (%) 14.6 22.5 0.65 (0.480.88) 0.005 0.61 (0.450.83) 0.002
aCox regression was performed using pooled data from multiple imputations. Data were missing for anaemia (n8), candidiasis (n56), WHO
clinical stage (n115). BMI (n115), HIV-RNA (n473). bVariables with p0.100 were not included in multivariable analysis. cPlasma HIV-
RNA was not included in the final model because of the many missing values. dAnaemia was defined asB11.0 g/dL for female andB13.0 g/dL
for male.
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to follow-up (44.8% vs. 28.9%) and one-year mortality (22.4%
vs. 11.6%) as compared to those who had a negative result,
also when corrected for possible confounding factors. To our
knowledge, this is one of the largest cohorts of HIV patients
examined so far and the first study from Indonesia.
The prevalence of serum cryptococcal antigenemia in our
cohort was comparable to previously published studies that
have screened HIV patients for circulating cryptococcal
antigen in the absence of signs suggesting meningitis. In
Uganda, cryptococcal antigenemia was found in 5.8% of 377
patients with a CD4 count below 100 cells/mL [9], in 8.8% of
295 similar patients from another study [10], and 19% in a
recent cross-sectional survey among 367 hospitalized pa-
tients with a median CD4 count of 23 [13]. In South Africa,
7% of 707 patients screened were positive, including 12.5%
of those with a CD4 count below 100 cells/mL [6]. A smaller
study among 131 ART-naı¨ve patients in Thailand found
cryptococcal antigen in 9.2%, especially among those with
a CD4 count below 100 cells/mL (n85, 12.9%) [12]. Finally,
in Cambodia, among a subgroup of 295 patients*most of
whom had a CD4 count below 100 cells/mL but none of
whom had signs of meningoencephalitis*10.8% were
positive [11].
In our study, one in every 10 patients with a positive serum
cryptococcal antigen test was diagnosed with cryptococcal
meningitis during follow-up. In fact, this number may have
been much higher as early loss to follow-up was very high
and significantly associated with cryptococcal antigenemia.
The majority of meningitis cases occurred after initiation of
ART, possibly due to the ‘‘unmasking’’ effect of ART [18].
The presence of serum cryptococcal antigen was associated
with at least a two-fold higher risk of death during follow-up,
also after correction for possible confounding factors. Similar
to the development of meningitis, our risk estimate for
increased mortality may be an underestimate, as many
cryptococcal antigen-positive patients who were classified as
early loss to follow-up may in fact have developed severe
cryptococcal meningitis leading to death. Mortality associated
with cryptococcal antigenemia appeared lower, and seemed to
occur somewhat later in our series (median time to death: 80
days) compared to a study in South Africa (median time to
death: 53 days) and Uganda (median survival: 26 days) [3,11],
but this may have been biased by the high loss to follow-up in
the first months in our study.
All patients in this cohort had an indication for ART, but
30% never started treatment, mostly because of early death
or loss to follow-up. We were unable to retrace those
patients who were lost to follow-up mainly because of fear
of breaching confidentiality and stigmatization. However, in
line with a systematic review and meta-analysis addressing
loss to follow-up among HIV patients [19], it seems likely that
many died.
This prevalence of cryptococcosis among asymptomatic
patients found in our setting emphasizes the importance of
screening patients with a low CD4 cell count for cryptococcal
antigen, as has been advocated by experts in this field, and
as was recently recommended by WHO [7,8,20,21]. After
completing this study we have implemented screening for
cryptococcal antigen for all ART-naı¨ve patients with a CD4
count below 100 cells/mL, followed by lumbar puncture for
those with a positive result, and pre-emptive fluconazole
treatment for those with a positive result but no meningitis.
A recently published study from Uganda showed that primary
prophylaxis of cryptococcal disease with fluconazole effec-
tively prevented development of cryptococcal meningitis and
cryptococcal-related death in HIV-positive individuals with no
cryptococcal antigenemia, although all-cause mortality was
not affected [22]. However, a targeted approach starting with
cryptococcal antigen testing for patients with a CD4 count
below 100 cells/mL prior to ART initiation may be more cost-
effective than universal prophylaxis for all patients with low
CD4 cell counts [10,21,22].
Our study suffers from several limitations. The outcome of
patients who were lost to follow-up could not be verified. In
addition, we may have missed cases of subclinical or mild
cryptococcal meningitis at baseline. Since cryptococcal anti-
gen testing was done retrospectively, no neurologist was
consulted and no lumbar puncture was performed if there
were no obvious signs of meningitis. On the other hand, as
part of an ongoing cohort study on meningitis in our hospital
[17,23], physicians in our HIV clinic have a high vigilance for
diagnosing meningitis. The study also suffers from the fact
that fluconazole use (for possible other purposes) was not
well recorded. Fluconazole, widely prescribed to patients
presenting with advanced HIV infection in this setting, may
have prevented the occurrence of overt meningitis and
subsequent death. As such, our study may actually have
underestimated the importance of cryptococcal antigenemia
in this setting.
Conclusions
Cryptococcal antigenemia was common and associatedwith at
least 10% attributable burden of death and loss to follow-up in
this large cohort of patients with advanced HIV in Indonesia.
Despite the limitations of our study, this large cohort with long
follow-up provides further evidence for the need to screen HIV
patients with a low CD4 cell count for serum cryptococcal
antigenemia, in an effort to reduce the high mortality of such
patients. Future studies should be conducted to optimize
screening and pre-emptive treatment of cryptococcosis.
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